PresentationPresentation Clinical Activity of the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Head & Neck Squamous Cell Carcinoma (HN-SCC) PDF (3.11 MB) Read MorePresentation Selinexor (KPT-330), an Oral, Selective Inhibitor of Nuclear Export (SINE) Shows Anti-Prostate Cancer (PrCa) Activity Preclinically & Disease Control in Patients (pts) with Chemotherapy Refractory, Castrate-Resistant Prostate Cancer (CRPC) PDF (2.86 MB) Read MorePresentation Evaluation of the novel, orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in spontaneous canine cancer: Results of phase I and phase II clinical trials PDF (592.72 KB) Read MorePresentation Evaluation of the Novel, Orally Bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 (Verdinexor) in Spontaneous Canine Cancer: Results of Phase I and Phase II Clinical Trials PDF (1.17 MB) Read MorePresentation The Combination of SELINEXOR (KPT-330), a Selective Inhibitor of Nuclear Export (SINE), and the FLT3 Inhibitor QUIZARTINIB Shows Anti-Tumor Activity in Acute Myeloid Leukemia (AML) In-Vitro and In-Vivo PDF (1.21 MB) Read MorePresentation Anti-Tumor Activity of SELINEXOR (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE), ± Dexamethasone in Multiple Myeloma Preclinical Models and Translation in Patients with Multiple Myeloma PDF (3.16 MB) Read MorePresentation A Phase 1 Dose Escalation Study of the Oral Selective Inhibitor of Nuclear Export (SINE) Selexinor (KPT-330) in Patients with Relapsed / Refractory Acute Myeloid Leukemia (AML) PDF (4.15 MB) Read MorePresentation A first in class, first in human phase I trial of KPT-330 (selinexor), a selective inhibitor of nuclear export (SINE) in patients with advanced solid tumors PDF (833.79 KB) Read MorePresentation A Phase 1 Dose Escalation Study of the Oral Selective Inhibitor of Nuclear Export (SINE) KPT-330 (Selinexor) in Patients with Relapsed / Refractory Acute Myeloid Leukemia (AML) PDF (744.21 KB) Read MorePresentation Pre-Clinical and Early Clinical Activity of the Oral Selective Inhibitor of Nuclear Export (SINE) Exportin 1 (XPO1) Antagonist Selinexor (KPT-330) in Patients with Platinum Resistant/Refractory Ovarian Cancer (OvCa) PDF (1.07 MB) Read More Previous 1 … 11 12 13 14 15 Next